

# PUBLIC SUBMISSION

|                                      |
|--------------------------------------|
| <b>As of:</b> 8/10/26, 7:36 AM       |
| <b>Received:</b> August 04, 2026     |
| <b>Status:</b> Posted                |
| <b>Posted:</b> August 10, 2026       |
| <b>Tracking No.</b> mse-8r9a-pndc    |
| <b>Comments Due:</b> August 10, 2026 |
| <b>Submission Type:</b> Web          |

**Docket:** CMS-2026-2179

Medicare Coverage of Items and Services for Coverage with Evidence Development (CMS-10697)

**Comment On:** CMS-2026-2179-0001

Medicare Coverage of Items and Services for Coverage with Evidence Development (CMS-10697)

**Document:** CMS-2026-2179-0002

Comment on CMS-2026-2179-0001

---

## Submitter Information

**Name:** Anonymous Anonymous

---

## General Comment

I appreciate the opportunity to comment on the Centers for Medicare & Medicaid Services (CMS) policy on Medicare Coverage of Items and Services for Coverage with Evidence Development (CED). I support CMS's continued use of Coverage with Evidence Development as it provides a balance between expanding access to innovative healthcare services and making sure that Medicare beneficiaries receive treatments supported by scientific evidence. As medical technology advances over the coming years, new treatments, procedures, and healthcare services are developed at a quick pace. Many of these innovations have the potential to improve patient outcomes, yet it is significantly important that Medicare coverage decisions are based on evidence displaying safety. The CED process will ensure that patients can access treatments as well as collect additional information to better understand their long-term benefits and risks.